ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients

ClinicalTrials.gov ID: NCT03927144

Public ClinicalTrials.gov record NCT03927144. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 11:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-month Prospective, Randomized, Interventional, Global, Multi-center, Active-controlled Study Comparing Sustained Benefit of Two Treatment Paradigms (AMG334 qm vs. Oral Prophylactics) in Adult Episodic Migraine Patients

Study identification

NCT ID
NCT03927144
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Amgen
Industry
Enrollment
621 participants

Conditions and interventions

Interventions

  • AMG334 Drug
  • Oral Prophylactic Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 14, 2019
Primary completion
Sep 30, 2021
Completion
Sep 29, 2022
Last update posted
Nov 17, 2023

2019 – 2022

United States locations

U.S. sites
20
U.S. states
14
U.S. cities
20
Facility City State ZIP Site status
Stanford Headache Center Stanford California 94305
Yale Center for Clinical Research New Haven Connecticut 06519
New England Institute for Neurology and Headache Stamford Connecticut 06905
George Washington Hospital Washington D.C. District of Columbia 20037
University of Miami Headache Division Miami Florida 33136
Premier Research Institute West Palm Beach Florida 33407
Diamond Headache Clinic Chicago Illinois 60642
Robbins Headache Clinic Riverwoods Illinois 60015
Medvadis Watertown Massachusetts 02472
New England Regional Headache Center, Inc Worcester Massachusetts 01605
MHNI Ann Arbor Michigan 48104
Clinical Research Institute Minneapolis Minnesota 55402
The Headache Center Ridgeland Mississippi 38157
Study Metrix Research City of Saint Peters Missouri 63303
Mercy Health Research St Louis Missouri 63141
Laszlo Mechtler Amherst New York 14226
Jefferson Headache Center Philadelphia Pennsylvania 19107
Nashville Neuroscience Group Nashville Tennessee 37203
Texas Neurology Dallas Texas 75214
Texas Institute for Neurological Disorders Sherman Texas 75092

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 92 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03927144, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 17, 2023 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03927144 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →